Moderna's cancer vaccine's long-term value may lie in its proprietary neoantigen selection algorithm. As a trade secret, it can't be easily replicated, effectively preventing generic competition indefinitely and creating a highly durable franchise as long as the treatment remains effective.

Previous cancer vaccine attempts using "shared antigens" failed. Moderna's success stems from creating a unique mRNA vaccine for each patient after discovering that roughly 90% of the targeted cancer antigens differ between individuals. This finding proves that a highly personalized approach is not just an edge case, but a core requirement for the therapy's efficacy.

The most common investor misconception is that cancer vaccines have "never worked." The key rebuttal is that past failures targeted generic, shared antigens. The new generation of vaccines is fundamentally different, targeting specific mutations unique to each patient's tumor, which changes the entire paradigm.

The recent momentum in cancer vaccines is not due to a single discovery. Instead, it's the culmination of decades of slow, steady progress in ancillary technologies like genetic sequencing, improved scientific understanding of tumors, and evolving regulatory frameworks, all maturing at the same time.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

Even though companies like Moderna (mRNA) and Transgene (viral vector) use different platforms, positive results from any of them help validate the entire individualized neoantigen approach for investors and clinicians. The massive unmet medical need ensures the market is large enough to support multiple successful players.

Unlike previous protein-based cancer vaccines that circulate in the blood, Moderna's mRNA enters antigen-presenting cells (APCs) in lymph nodes. The mRNA message is then translated inside the immune cells, presenting the cancer signature "from within." This creates a more robust and specific T-cell response, a crucial differentiator that led to success where others failed.

Verge Labs warns that the biggest risk to AI in healthcare is losing interest after early failures. True breakthroughs come from iterating and learning. Instead of burying a failed trial, they published the results and used the data to improve their platform, viewing it as a "hard-won lesson."

While Moderna's Phase 3 success is a scientific breakthrough, its real-world application is uncertain. The personalized nature creates a significant manufacturing burden and high cost, raising questions about whether payers will reimburse an expensive therapy used to delay, not cure, cancer in a broad adjuvant setting.